+关注
瑞琳焊机_7931
暂无个人介绍
IP属地：江苏
3
关注
0
粉丝
0
主题
0
勋章
主贴
热门
瑞琳焊机_7931
2025-04-18
$礼来(LLY)$
美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3546938139179508","uuid":"3546938139179508","gmtCreate":1583844117627,"gmtModify":1634349872507,"name":"瑞琳焊机_7931","pinyin":"rlhj7931ruilinhanji7931","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/7a02f027767c491bcfdca8d3589a7a4c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"江苏","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":425616621260920,"gmtCreate":1744919968570,"gmtModify":1744921103250,"author":{"id":"3546938139179508","authorId":"3546938139179508","name":"瑞琳焊机_7931","avatar":"https://static.tigerbbs.com/7a02f027767c491bcfdca8d3589a7a4c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546938139179508","authorIdStr":"3546938139179508"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> ","listText":"<a href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> ","text":"$礼来(LLY)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/425616621260920","repostId":"2528719246","repostType":2,"repost":{"id":"2528719246","kind":"news","pubTimestamp":1744897237,"share":"https://www.laohu8.com/m/news/2528719246?lang=zh_CN&edition=full","pubTime":"2025-04-17 21:40","market":"us","language":"zh","title":"美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic","url":"https://stock-news.laohu8.com/highlight/detail?id=2528719246","media":"华尔街见闻","summary":"服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。礼来股价在美股盘前交易中飙升14%，而诺和诺德欧股跌近6.8%。","content":"<html><head></head><body><blockquote><p>服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。 </p></blockquote><p>4月17日，礼来盘初涨超16%，公司的口服减肥药Orforglipron在三期临床试验中表现出色，有望成为无需注射的减肥药替代品。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fac5ba6ba0d75b844f9a7213ab58a3e4\" tg-width=\"560\" tg-height=\"240\"/></p><p>试验结果显示，礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。<strong>服用Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。</strong></p><p>此外，这款口服药还平均降低了血糖水平1.3%，而Ozempic降低了2.1%。</p><h2 id=\"id_2036632377\">竞争对手接连受挫</h2><p>本周早些时候，辉瑞公司宣布停止开发口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。</p><p>而诺和诺德本月痛失欧股市值老大。自去年6月以来，诺和诺德持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳。</p><p>在竞争对手表现不佳的背景下，礼来公司的研究备受关注。根据临床试验数据库，<strong>该公司的主要肥胖症试验最早将于7月完成。如果一切顺利，该公司可能最早在2026年初获得肥胖症适应症的批准。</strong></p></body></html>","source":"wallstreetcn_hot_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-17 21:40 北京时间 <a href=https://wallstreetcn.com/articles/3745424><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。 4月17日，礼来盘初涨超16%，公司的口服减肥药Orforglipron在三期临床试验中表现出色，有望成为无需注射的减肥药替代品。试验结果显示，礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。服用...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3745424\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/54b138fe6c8c9fd6dabf7feab262ebb6","relate_stocks":{"LLY":"礼来"},"source_url":"https://wallstreetcn.com/articles/3745424","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2528719246","content_text":"服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。 4月17日，礼来盘初涨超16%，公司的口服减肥药Orforglipron在三期临床试验中表现出色，有望成为无需注射的减肥药替代品。试验结果显示，礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。服用Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。此外，这款口服药还平均降低了血糖水平1.3%，而Ozempic降低了2.1%。竞争对手接连受挫本周早些时候，辉瑞公司宣布停止开发口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。而诺和诺德本月痛失欧股市值老大。自去年6月以来，诺和诺德持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳。在竞争对手表现不佳的背景下，礼来公司的研究备受关注。根据临床试验数据库，该公司的主要肥胖症试验最早将于7月完成。如果一切顺利，该公司可能最早在2026年初获得肥胖症适应症的批准。","news_type":1,"symbols_score_info":{"LLY":1.1}},"isVote":1,"tweetType":1,"viewCount":883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":425616621260920,"gmtCreate":1744919968570,"gmtModify":1744921103250,"author":{"id":"3546938139179508","authorId":"3546938139179508","name":"瑞琳焊机_7931","avatar":"https://static.tigerbbs.com/7a02f027767c491bcfdca8d3589a7a4c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3546938139179508","idStr":"3546938139179508"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> ","listText":"<a href=\"https://laohu8.com/S/LLY\">$礼来(LLY)$ </a> ","text":"$礼来(LLY)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/425616621260920","repostId":"2528719246","repostType":2,"repost":{"id":"2528719246","kind":"news","pubTimestamp":1744897237,"share":"https://www.laohu8.com/m/news/2528719246?lang=zh_CN&edition=full","pubTime":"2025-04-17 21:40","market":"us","language":"zh","title":"美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic","url":"https://stock-news.laohu8.com/highlight/detail?id=2528719246","media":"华尔街见闻","summary":"服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。礼来股价在美股盘前交易中飙升14%，而诺和诺德欧股跌近6.8%。","content":"<html><head></head><body><blockquote><p>服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。 </p></blockquote><p>4月17日，礼来盘初涨超16%，公司的口服减肥药Orforglipron在三期临床试验中表现出色，有望成为无需注射的减肥药替代品。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fac5ba6ba0d75b844f9a7213ab58a3e4\" tg-width=\"560\" tg-height=\"240\"/></p><p>试验结果显示，礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。<strong>服用Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。</strong></p><p>此外，这款口服药还平均降低了血糖水平1.3%，而Ozempic降低了2.1%。</p><h2 id=\"id_2036632377\">竞争对手接连受挫</h2><p>本周早些时候，辉瑞公司宣布停止开发口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。</p><p>而诺和诺德本月痛失欧股市值老大。自去年6月以来，诺和诺德持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳。</p><p>在竞争对手表现不佳的背景下，礼来公司的研究备受关注。根据临床试验数据库，<strong>该公司的主要肥胖症试验最早将于7月完成。如果一切顺利，该公司可能最早在2026年初获得肥胖症适应症的批准。</strong></p></body></html>","source":"wallstreetcn_hot_news","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-17 21:40 北京时间 <a href=https://wallstreetcn.com/articles/3745424><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。 4月17日，礼来盘初涨超16%，公司的口服减肥药Orforglipron在三期临床试验中表现出色，有望成为无需注射的减肥药替代品。试验结果显示，礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。服用...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3745424\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/54b138fe6c8c9fd6dabf7feab262ebb6","relate_stocks":{"LLY":"礼来"},"source_url":"https://wallstreetcn.com/articles/3745424","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2528719246","content_text":"服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。 4月17日，礼来盘初涨超16%，公司的口服减肥药Orforglipron在三期临床试验中表现出色，有望成为无需注射的减肥药替代品。试验结果显示，礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。服用Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。此外，这款口服药还平均降低了血糖水平1.3%，而Ozempic降低了2.1%。竞争对手接连受挫本周早些时候，辉瑞公司宣布停止开发口服减肥药Danuglipron，原因是临床试验中一名患者出现潜在与药物相关的肝损伤。而诺和诺德本月痛失欧股市值老大。自去年6月以来，诺和诺德持续遭遇一连串利空，包括减重药Wegovy和Ozempic需求不及预期、口服减重药monlunabant的中期试验结果令人失望，以及另一款在研注射药物CagriSema的数据表现不佳。在竞争对手表现不佳的背景下，礼来公司的研究备受关注。根据临床试验数据库，该公司的主要肥胖症试验最早将于7月完成。如果一切顺利，该公司可能最早在2026年初获得肥胖症适应症的批准。","news_type":1,"symbols_score_info":{"LLY":1.1}},"isVote":1,"tweetType":1,"viewCount":883,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
